ESMO-THE CHRISTIE PRECEPTORSHIP PROGRAMME LUNG CANCER

Multidisciplinary management, standards of care and future perspectives

Manchester, United Kingdom 12-14 March 2025

CO-CHAIRS

Fiona Blackhall, United Kingdom Raffaele Califano, United Kingdom Pilar Garrido López, Spain

SPEAKERS

Paul Baas, Netherlands
Haval Balata, United Kingdom
Claire Barker, United Kingdom
Richard Booton, United Kingdom
Clara Chan, United Kingdom
Christopher Craig, United Kingdom
Simon Ekman, Sweden
Corinne Faivre-Finn, United Kingdom
Enriqueta Felip, Spain
Lizza Hendriks, Netherlands
Keith M. Kerr, United Kingdom
Jennifer A. King, United Kingdom

Rohit Kochhar, United Kingdom Cécile Le Péchoux, France Colin Lindsay, United Kingdom Luis Paz-Ares, Spain David Planchard, France Martin Reck, Germany Christina H. Ruhlmann, Denmark Suresh Senan, Netherlands Yvonne Summers, United Kingdom Fiona Thistlethwaite, United Kingdom Paul E. Van Schil, Belgium Giulia Veronesi, Italy

LEARNING OBJECTIVES

- To learn about the evidence-base for lung cancer screening and novel diagnostic modalities
- To learn about the management of early-stage NSCLC and use of adjuvant treatments
- To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
- To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC
- To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about treatment of NSCLC with oligometastatic disease
- To learn about the systemic treatment of mesothelioma and SCLC
- To learn about the role of supportive and palliative care for thoracic malignancies

ACCREDITATION

The programme of this event has been accredited with 16 ESMO-MORA category 1 points.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

Johnson&Johnson

Wednesday, 12 March 2025

08:15-09:15 60'	Registration	
09:15-09:25 10'	Welcome & Introduction	Fiona Blackhall, UK Raffaele Califano, UK Pilar Garrido López, ES
09:25-12:25 180'	SESSION 1 Screening and diagnostics for lung cancer	Co-Chairs: Raffaele Califano, UK Fiona Blackhall, UK
30'	Lung cancer screening	Haval Balata, UK
30'	EBUS TBNA in diagnosis/staging of lung cancer	Richard Booton, UK
10:25-10:55	Coffee break	
30'	Role of pathologist in diagnosis and mutation analysis of lung cancer	Keith M. Kerr, UK
30'	PET/CT in staging of lung cancer	Rohit Kochhar, UK
30'	Diagnosis and management of malignant pleural effusion	Christopher Craig, UK
12:25-13:25	Lunch	
13:25-16:25 180'	SESSION 2 Radical treatment of early stage NSCLC	Co-Chairs: Cécile Le Péchoux, FR Giulia Veronesi, IT
30'	Surgery for early-stage NSCLC	Giulia Veronesi, IT
30'	Stereotactic ablative RT for early-stage NSCLC	Suresh Senan, The Netherlands
30'	Adjuvant radiotherapy for completely resected early-stage NSCLC	Cécile Le Péchoux, FR
14:55-15:25	Coffee break	
30'	Adjuvant systemic therapies for resected early-stage NSCLC	Raffaele Califano, UK
30'	Perioperative immunotherapy-based strategies for resectable NSCLC	Yvonne Summers, UK
16:25-17:25 60'	SESSION 3 Locally advanced NSCLC	Co-Chairs: Clara Chan, UK Paul E. Van Schil, BE
30'	Combined modality treatment for unresectable NSCLC	Clara Chan, UK
30'	Role of surgery for N2 disease	Paul E. Van Schil, BE
17:25-17:35 10'	Close of day 1	Fiona Blackhall, UK Raffaele Califano, UK Pilar Garrido López, ES

Thursday, 13 March 2025

09:00-12:00 180'	SESSION 4 Advanced NSCLC	Co-Chairs: Fiona Blackhall, UK Martin Reck, DE
30'	First-line immune-checkpoint blockade for advanced NSCLC	Luis Paz-Ares, ES
30'	First-line chemotherapy for advanced NSCLC	David Planchard, FR
30'	Second-line treatment for advanced NSCLC	Martin Reck, DE
10:30-11:00	Coffee break	
30'	Treatment of EGFR mutant advanced NSCLC	Raffaele Califano, UK
30'	Treatment of ALK and ROS1 positive advanced NSCLC	Fiona Blackhall, UK
12:00-13:00	Lunch	
13:00-14:30 90'	SESSION 5 Palliative treatment of lung cancer and mesothelioma	Co-Chairs: Pilar Garrido López, ES Simon Ekman, SE
30'	Treatment of advanced NSCLC harboring KRAS mutation and MET aberrations	Colin Lindsay, UK
30'	Beyond EGFR, ALK, ROS1, KRAS and MET: Novel molecularly driven targeted therapies in NSCLC	Simon Ekman, SE
30'	Treatment of oligometastatic NSCLC	Lizza Hendriks, NL
14:30-15:00	Coffee break	
14:30-15:00 15:00-17:30 150'	SESSION 5 - cont. Palliative treatment of lung cancer and mesothelioma	Co-Chairs: Paul Baas, NL Christina H. Ruhlmann, DK
15:00-17:30	SESSION 5 - cont.	Paul Baas, NL
15:00-17:30 150'	SESSION 5 - cont. Palliative treatment of lung cancer and mesothelioma	Paul Baas, NL Christina H. Ruhlmann, DK
15:00-17:30 150'	SESSION 5 - cont. Palliative treatment of lung cancer and mesothelioma Systemic treatment of mesothelioma Radical treatment of brain metastases: The importance of a	Paul Baas, NL Christina H. Ruhlmann, DK Paul Baas, NL
15:00-17:30 150' 30' 30'	SESSION 5 - cont. Palliative treatment of lung cancer and mesothelioma Systemic treatment of mesothelioma Radical treatment of brain metastases: The importance of a neuro-oncology multi-disciplinary approach	Paul Baas, NL Christina H. Ruhlmann, DK Paul Baas, NL Jennifer A. King, UK
15:00-17:30 150' 30' 30' 30'	SESSION 5 - cont. Palliative treatment of lung cancer and mesothelioma Systemic treatment of mesothelioma Radical treatment of brain metastases: The importance of a neuro-oncology multi-disciplinary approach Supportive and palliative care in lung cancer	Paul Baas, NL Christina H. Ruhlmann, DK Paul Baas, NL Jennifer A. King, UK Christina H. Ruhlmann, DK
15:00-17:30 150' 30' 30' 30' 60' 17:30-17:40	SESSION 5 - cont. Palliative treatment of lung cancer and mesothelioma Systemic treatment of mesothelioma Radical treatment of brain metastases: The importance of a neuro-oncology multi-disciplinary approach Supportive and palliative care in lung cancer Participants clinical case discussion (6x10')	Paul Baas, NL Christina H. Ruhlmann, DK Paul Baas, NL Jennifer A. King, UK Christina H. Ruhlmann, DK Faculty Fiona Blackhall, UK Raffaele Califano, UK
15:00-17:30 150' 30' 30' 30' 60' 17:30-17:40 10'	SESSION 5 - cont. Palliative treatment of lung cancer and mesothelioma Systemic treatment of mesothelioma Radical treatment of brain metastases: The importance of a neuro-oncology multi-disciplinary approach Supportive and palliative care in lung cancer Participants clinical case discussion (6x10') Close of day 2	Paul Baas, NL Christina H. Ruhlmann, DK Paul Baas, NL Jennifer A. King, UK Christina H. Ruhlmann, DK Faculty Fiona Blackhall, UK Raffaele Califano, UK

Each 10-minute slot for clinical case discussion includes a 5' case presentation and an 5' Q&A / panel discussion

Friday, 14 March 2025

09:00-10:30 90'	SESSION 6 SCLC	Co-Chairs: Corinne Faivre-Finn, UK Pilar Garrido López, ES
30'	Treatment of limited stage SCLC	Corinne Faivre-Finn, UK
30'	First-line chemo-immunotherapy for SCLC	Pilar Garrido López, ES
30'	Second-line therapies for SCLC	Enriqueta Felip, ES
10:30-11:00	Coffee break	
11:00-12:30 90'	SESSION 6 - cont. SCLC	Co-Chairs: Fiona Blackhall, UK Raffaele Califano, UK
30'	Novel targeted therapies in SCLC	Fiona Blackhall, UK
30'	Prophylactic cranial irradiation and role of thoracic RT for extensive stage SCLC	Claire Barker, UK
30'	Next generation therapeutics for lung cancer	Fiona Thistlethwaite, UK
12:30-12:35 5'	Conclusion and farewell	Fiona Blackhall, UK Raffaele Califano, UK Pilar Garrido López, ES
12:35-13:35	Lunch	